The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.75
Bid: 48.50
Ask: 49.00
Change: -0.50 (-1.02%)
Spread: 0.50 (1.031%)
Open: 48.00
High: 50.25
Low: 48.00
Prev. Close: 48.80
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

Wed, 22nd Dec 2021 12:21

(Alliance News) - Stock prices were slightly higher at midday on Wednesday as investors mulled the likelihood of further Omicron restrictions being imposed and awaited US economic growth data in the afternoon.

The FTSE 100 index was up just 0.56 of a point at 7,297.79. The mid-cap FTSE 250 index was faring better, up 141.93 points, or 0.6%, at 22,962.27. The AIM All-Share index was up 4.78 points, or 0.4%, at 1,178.35.

The Cboe UK 100 index was up 0.2% at 724.37. The Cboe 250 was up 0.7% at 20,362.10. The Cboe Small Companies was up 0.4% at 14,864.54.

In mainland Europe, the CAC 40 stock index in Paris was up 0.2%, while the DAX 40 in Frankfurt was 0.3% higher.

"Investors are preparing to go into hibernation for Christmas and will hope by this time next week we'll know a lot more about the trajectory of Omicron and the likelihood of further restrictions to contain it, and just how long those curbs will be in place," said AJ Bell's Russ Mould. "For now the markets, bar the odd day, have just about managed to hold on to the idea that, to employ central bankers' favourite word of 2021, Omicron's impact will be transitory."

In the FTSE 100, Taylor Wimpey was up 1.3%.

The housebuilder committed to removing terms from contracts that double ground rents for leaseholders every 10 years, the UK Competition & Markets Authority confirmed.

Taylor Wimpey said the CMA investigation into the historical sale of leasehold properties with doubling ground rent clauses by the company is closed, following the agreement of voluntary undertakings.

The High Wycombe, England-based firm said the cost of the undertakings falls within the original provision it made in 2017. By entering into the undertakings there is no finding that Taylor Wimpey has infringed UK consumer law, it noted.

At the other end of London large-caps, Croda International was the worst performer, down 1.7%. The speciality chemicals company has agreed to sell the majority of its Performance Technologies and Industrial Chemicals businesses to Cargill for an enterprise value of EUR915 million on a cash-free, debt-free basis.

Croda said the disposal of the businesses follows the strategic review that it announced in May. The operations being sold represent 77% of PTIC's 2020 revenue and consist of five manufacturing facilities in the UK, China and the Netherlands.

Land Securities was down 0.3%. The property developer bought a further stake in the Bluewater shopping mall outside London.

Landsec said it has completed the acquisition of an additional 25% share in Bluewater from Lendlease Retail Partnership for GBP172 million, representing a net initial yield of 8.15% and an equivalent yield of 8.25%.

In a separate deal, Landsec said it will sell 25% of this share - a 7.5% stake - to co-owner M&G for its pro rata share of the purchase price with the deal completing in April 2022.

M&G shares were up 1.3%.

In the FTSE 250, Syncona was the best performer, up 7.5%, after the healthcare investor said its portfolio company Gyroscope Therapeutics will be sold to Swiss pharmaceutical maker Novartis for up to USD1.5 billion.

Syncona has a 54% stake in Gyroscope following a USD42 million investment in March, after co-founding the business in 2016. In a bumper payday, Syncona will receive upfront cash proceeds of GBP334 million from the deal, representing a GBP180 million uplift to the current holding value.

Novartis shares were down 0.6% in Zurich.

Conversely, Grafton was down 1.1%. The Dublin-based building materials firm acquired Cork-based building materials supplier Sitetech Building Products. Grafton did not disclose a purchase price. Sitetech had revenue of EUR17 million in 2020. Grafton noted the acquisition is subject to approval by the Competition & Consumer Protection Commission in Ireland.

On AIM, Avacta was up 22% after it said its AffiDX Covid-19 antigen lateral flow test has received a CE mark for consumer self-test use in the UK and EU.

The pound was quoted at USD1.3315 at midday on Wednesday, up from USD1.3248 at the London equities close Tuesday.

UK Prime Minister Boris Johnson on Tuesday gave the go-ahead for people's Christmas plans, although he warned tougher restrictions could be implemented post-December 25.

The announcement gave the pound some support, said analysts at OFX.

The euro was priced at USD1.1298, higher against USD1.1267 late Tuesday. Against the Japanese yen, the dollar was trading at JPY114.20, firm from JPY114.14.

Brent oil was quoted at USD74.14 a barrel on Wednesday at midday, up from USD73.48 late Tuesday. Gold stood at USD1,790.23 an ounce, up from USD1,785.40.

US stock index futures were pointing to a mixed start on Wall Street as investors look for clarity over the economic impact of the Omicron variant and the future of the Biden administration's USD2 trillion stimulus plan.

The Dow Jones Industrial Average was called up 0.1%, the S&P 500 flat and the Nasdaq Composite down 0.1%.

The year-and-a-half-long rally across markets has petered out in recent weeks on fears about the new Covid variant and government measures to contain the spread. This comes just as central banks begin to remove the vast financial support put in place at the start of the pandemic.

US investors remain hopeful of a resolution to the latest political impasse after US President Joe Biden said he was optimistic he could win the key vote of Democratic Senator Joe Manchin, who threw the president's economic agenda into doubt after he said Sunday he would reject the present stimulus proposal.

On the corporate front, Merck & Co was up 1.8% in pre-market trade in New York. The drugmaker said the UK government has ordered an additional 1.8 million courses of molnupiravir, its investigational oral antiviral Covid-19 drug.

Wednesday's economic calendar has a third estimate on US third-quarter gross domestic product at 1330 GMT. This is expected to show an annualised increase of 2.1%, unchanged from the second reading.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
19 Jun 2023 07:53

LONDON BRIEFING: Severn Trent deal sized up by CMA; Coca-Cola HBC buys

(Alliance News) - Stocks in London are called lower on Monday, ahead of more central bank decisions, while a meeting between US Secretary of State Antony Blinken and his Chinese counterpart put relations between the two nations back under the spotlight.

Read more
5 Jun 2023 12:28

Avacta triggers second milestone payment in AffyXell venture

(Sharecast News) - Life science company Avacta Group announced on Monday that a second milestone equity payment had been triggered, resulting in an increased shareholding for Avacta in AffyXell Therapeutics.

Read more
5 Jun 2023 12:06

Avacta sees shares rise on new equity payment for South Korea venture

(Alliance News) - Avacta Group PLC on Monday celebrated "rapid" progress on its joint venture in South Korea, following a second equity payment.

Read more
1 Jun 2023 14:53

Avacta buys Belgium-based Coris Bioconcept for £7.4m

(Sharecast News) - Life science company Avacta Group announced the acquisition of Coris Bioconcept for initial cash consideration of £7.4m on Thursday.

Read more
1 Jun 2023 10:24

Avacta enhances rapid test portfolio with GBP7.4 million Coris buy

(Alliance News) - Avacta Group PLC on Thursday said that it has bought Coris Bioconcept SRL, adding a range of professional-use rapid tests to its product portfolio.

Read more
27 Apr 2023 14:34

TRADING UPDATES: Volex wins contract; Engage XR revenue jumps

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
27 Apr 2023 12:11

Avacta doses first patient in US tumour treatment trial

(Sharecast News) - Oncology and diagnostics developer Avacta announced the dosing of the first patient in the United States under its investigational new drug (IND) application on Thursday - a milestone for its first therapeutic product 'AVA6000', based on its proprietary 'preCISION' technology.

Read more
25 Apr 2023 14:39

EARNINGS SUMMARY: hVIVO sees 30% revenue growth; Next 15 lifts payout

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
25 Apr 2023 13:51

Revenue rises, adjusted EBITDA loss improves for Avacta

(Sharecast News) - Oncology-focussed drugs and diagnostics developer Avacta reported full-year revenue of £9.7m in its preliminary results on Tuesday, up from £2.9m year-on-year.

Read more
18 Apr 2023 15:47

UK earnings, trading statements calendar - next 7 days

Wednesday 19 April 
Antofagasta PLCTrading Statement
discoverIE Group PLCTrading Statement
Distribution Finance Capital Holdings PLCFull Year Results
Hunting PLCTrading Statement
Just Eat Takeaway.com NVTrading Statement
Kainos Group PLCTrading Statement
Liontrust Asset Management PLCTrading Statement
M Winkworth PLCFull Year Results
Network International Holdings PLCTrading Statement
Thursday 20 April 
AJ Bell PLCTrading Statement
Arix Bioscience PLCFull Year Results
Centamin PLCTrading Statement
Deliveroo PLCTrading Statement
Dianomi PLCFull Year Results
Dunelm Group PLCQ3 Results
Foxtons Group PLCTrading Statement
GB Group PLCTrading Statement
Hochschild Mining PLCFull Year Results
Intelligent Ultrasound Group PLCFull Year Results
Oxford BioMedica PLCFull Year Results
PensionBee Group PLCTrading Statement
Rentokil Initial PLCTrading Statement
Rio Tinto PLCTrading Statement
Senior PLCTrading Statement
Segro PLCTrading Statement
WH Smith PLCHalf Year Results
Friday 21 April 
Angle PLCFull Year Results
BHP Group LtdTrading Statement
Lookers PLCFull Year Results
Monday 24 April 
Brighton Pier Group PLCFull Year Results
CentralNic Group PLCTrading Statement
Checkit PLCFull Year Results
Egdon Resources PLCHalf Year Results
Keystone Law Group PLCFull Year Results
Lok'n Store Group PLCHalf Year Results
Novacyt SAFull Year Results
Tuesday 25 April 
AB Dynamics PLCHalf Year Results
Anglo American PLCTrading Statement
Associated British Foods PLCHalf Year Results
Avacta Group PLCFull Year Results
Banco Santander SAQ1 Results
Card Factory PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Corero Network Security PLCFull Year Results
Dillistone Group PLCFull Year Results
Focusrite PLCHalf Year Results
IWG PLCTrading Statement
Jadestone Energy PLCFull Year Results
Next Fifteen Communications Group PLCFull Year Results
Northcoders Group PLCFull Year Results
Petrofac LtdFull Year Results
Quilter PLCTrading Statement
Resolute Mining LtdTrading Statement
RWS Holdings PLCTrading Statement
Travis Perkins PLCTrading Statement
WAG Payment Solutions PLCTrading Statement
Whitbread PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
17 Apr 2023 09:43

Avacta presents pre-clinical data for anti-cancer candidate

(Sharecast News) - Life science company Avacta Group announced the presentation of pre-clinical data for its novel 'preCISION' proteasome inhibitor AVA3996 on Monday.

Read more
6 Apr 2023 12:14

Avacta opens first two clinical investigator sites in US for AVA6000

(Alliance News) - Avacta Group PLC on Thursday said it opened its first two clinical investigator sites for the phase 1 clinical trial of AVA6000 on Wednesday, under it US investigational new drug application.

Read more
6 Apr 2023 10:09

Avacta opens first US clinical investigator sites

(Sharecast News) - Life sciences company Avacta has opened its first two clinical investigator sites in the US for a Phase 1 clinical study on its AVA6000 candidate.

Read more
5 Apr 2023 12:51

Avacta doses first patient in higher-dose oncology cohort

(Sharecast News) - Life sciences company Avacta Group announced that it had dosed the first patient in the fifth cohort of the first-in-human phase one trial of its innovative oncology drug 'AVA6000' on Wednesday.

Read more
5 Apr 2023 12:12

Avacta doses first patient in fifth cohort of AVA6000 phase 1 study

(Alliance News) - Avacta Group PLC on Wednesday said the first patient has been dosed in the fifth cohort of the first-in-human phase 1 trial of AVA6000, a novel form of doxorubicin designed to improve its safety and therapeutic index.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.